Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- Korean Breast Cancer Study Group
- Target Recruit Count
- 1234
- Registration Number
- NCT00912548
- Locations
- 🇰🇷
Department of Surgery, Korea Cancer Center Hospital, Seoul, Korea, Republic of
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT00884273
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇫🇮KYS/kirurgian klin (Kuopio), Kuopio, Finland
Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
- Conditions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Ramathibodi Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00851461
- Locations
- 🇹🇭
Medical Genetics and Molecular Medicine Unit,, Department of Medicine, Ramathibodi Hospital, Bangkok, Thailand
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT00833248
- Locations
- 🇬🇧
Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom
🇫🇷Clinique du Parc, Toulouse, France
🇫🇷Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT00831233
- Locations
- 🇪🇸
Fundación Puigvert, Barcelona, Spain
🇪🇸Fundacion Hospital Alcorcón, Alcorcon, Spain
🇪🇸Hospital de Basurto, Bilbao (Bizkaia), Spain
Zoladex Plus Tamoxifen in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00827307
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00771017
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT00769795
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 48
- Registration Number
- NCT00651326
- Locations
- 🇨🇦
McGill University - Dept. Oncology, Montreal, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00631527
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.